SEC Filing Summary: Cerulean Pharma Inc. (8-K)
Business Context and Reporting Period
This Form 8-K was filed by Cerulean Pharma Inc. on June 1, 2017, reporting events occurring between May 19, 2017, and June 1, 2017. The filing addresses the company's compliance status with NASDAQ listing requirements and the subsequent transfer of its stock listing.
Key Financial Metrics
- Stockholders' Equity: $7,741,000 (as of March 31, 2017, per Form 10-Q).
- Minimum Equity Requirement (NASDAQ Global Market): $10,000,000.
- Stock Symbol: CERU.
- Other Metrics: The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity beyond the equity figure.
Material Changes and Listing Status
The company was notified on May 19, 2017, that it failed to meet the $10,000,000 minimum stockholders' equity requirement for the NASDAQ Global Market. Consequently, the company applied on May 25, 2017, to transfer its listing to the NASDAQ Capital Market. NASDAQ approved this transfer on June 1, 2017, effective June 5, 2017.
Additionally, the company remains non-compliant with the minimum bid price requirement of $1.00 per share (Rule 5450(a)(1)), having closed below this threshold for 30 consecutive business days prior to May 5, 2017.
Outlook, Risks, and Contingencies
- Compliance Deadline: The company has until November 1, 2017, to demonstrate compliance with the minimum bid price requirement.
- Contingency: If the company fails to meet the bid price requirement by the deadline, it may be eligible for an additional compliance period if it meets the market value of publicly held shares and other initial listing requirements for the NASDAQ Capital Market.
- Trading Continuity: The stock will continue to trade under the symbol "CERU" on the NASDAQ Capital Market.
Key Facts for Investor Verification
- Verify the current stock price to assess progress toward the $1.00 minimum bid price requirement.
- Confirm the effective date of the listing transfer (June 5, 2017) and any associated trading changes.
- Monitor the November 1, 2017, deadline for bid price compliance to evaluate delisting risk.
- Review the most recent Form 10-Q for detailed financial statements regarding the $7,741,000 equity balance.